Essex Property Trust, Inc. vs Nuwellis Inc — how do they compare? Essex Property Trust, Inc. trades at $297.51 (market cap $18.82B), while Nuwellis Inc trades at $2.85 (market cap $1.10M). The key difference: Essex Property Trust, Inc. is far larger — about 17109.1× Nuwellis Inc's market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| ESS | NUWE | |
|---|---|---|
Market Cap | $18.82B | $1.10M |
Sector | Real Estate | Technology |
52-Week High | $298.33 | $558.26 |
52-Week Low | $239.61 | $2.80 |
Enterprise Value | $25.54B | -$709.83K |
Dividend Yield | 3.54% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.
The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.
Trailing returns across standard periods
Latest headlines on both assets
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →